An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Name: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
Published: 2022
License: Public Domain

Novartis Pharmaceuticals · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

extension

chronic spontaneous urticaria, csu, brutons tyrosine kinase (btk) inhibitor, urticaria activity score, hives severity score, itch severity score, extension, randomized withdrawal, retreatment upon relapse, remibrutinib, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Related documents